Baird Maintains Outperform on Axsome Therapeutics, Lowers Price Target to $220

Benzinga · 1d ago
Baird analyst Joel Beatty maintains Axsome Therapeutics (NASDAQ:AXSM) with a Outperform and lowers the price target from $246 to $220.